oe19 gastric oesophagal carcinoma hpa cultures rpmi1640 (ATCC)
99
Structured Review
ATCC
oe19 gastric oesophagal carcinoma hpa cultures rpmi1640
Oe19 Gastric Oesophagal Carcinoma Hpa Cultures Rpmi1640, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 19636 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oe19+gastric/RPMI-1640+Medium/us09989536-647-58-77
Average 99 stars, based on 19636 article reviews
Oe19 Gastric Oesophagal Carcinoma Hpa Cultures Rpmi1640, supplied by ATCC, used in various techniques. Bioz Stars score: 99/100, based on 19636 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/oe19+gastric/RPMI-1640+Medium/us09989536-647-58-77
Average 99 stars, based on 19636 article reviews
oe19 gastric oesophagal carcinoma hpa cultures rpmi1640 - by Bioz Stars,
2026-10
99/100 stars
Images
Related Articles
XTT Assay:Article Title: Binding molecules with antitumoral activity Article Snippet: .. XTT assay conditions incuation time with Cell line Description Distributor growth medium cells/well seeded anti-HER2 agents NCl-N87 gastric carcinoma, liver ATCC RPMI1640 + 10% FBS 7000 5 days metastasis BT-474 breast, ductal carcinoma ATCC DMEM/F12 + insulin + 7000 5 days 10% FBS KPL-4 breast, malignant pleural Prof. DMEM + 10% FBS 2000 3 days effusion Kurebayashi* Modification:Article Title: Binding molecules with antitumoral activity Article Snippet: .. XTT assay conditions incuation time with Cell line Description Distributor growth medium cells/well seeded anti-HER2 agents NCl-N87 gastric carcinoma, liver ATCC RPMI1640 + 10% FBS 7000 5 days metastasis BT-474 breast, ductal carcinoma ATCC DMEM/F12 + insulin + 7000 5 days 10% FBS KPL-4 breast, malignant pleural Prof. DMEM + 10% FBS 2000 3 days effusion Kurebayashi* Multiple Displacement Amplification:Article Title: Binding molecules with antitumoral activity Article Snippet: .. XTT assay conditions incuation time with Cell line Description Distributor growth medium cells/well seeded anti-HER2 agents NCl-N87 gastric carcinoma, liver ATCC RPMI1640 + 10% FBS 7000 5 days metastasis BT-474 breast, ductal carcinoma ATCC DMEM/F12 + insulin + 7000 5 days 10% FBS KPL-4 breast, malignant pleural Prof. DMEM + 10% FBS 2000 3 days effusion Kurebayashi* |